Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

222 Press Releases
DateTitleCompany
11 Mar 13 Pharmaco-invasive strategy including Metalyse® delivers comparable clinical outcomes to primary PCI for STEMI patients who could not undergo primary PCI within one hour from first medical contact Boehringer Ingelheim
11 Mar 13 American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education with focus on China in 2013 Boehringer Ingelheim,
Published by
Business Wire
23 Feb 13 Phase III results: tiotropium* Respimat® is effective in symptomatic asthma patients irrespective of their allergic status Boehringer Ingelheim,
Published by
Business Wire
30 Jan 13 FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD Boehringer Ingelheim
30 Jan 13 FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol* for Maintenance Treatment of COPD Boehringer Ingelheim,
Published by
Business Wire
16 Jan 13 U.S. FDA Grants Priority Review to Boehringer Ingelheim’s Afatinib* NDA for EGFR Mutation-Positive Advanced NSCLC Boehringer Ingelheim,
Published by
Business Wire
08 Jan 13 Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin Boehringer Ingelheim and Eli Lilly and Company,
Published by
Boehringer Ingelheim
10 Dec 12 Treatment with Pradaxa® associated with better patient outcomes after a major bleeding event compared to warfarin Boehringer Ingelheim,
Published by
Business Wire
05 Dec 12 New Pradaxa® safety and efficacy data to be featured at ‘Best of ASH’ session Boehringer Ingelheim,
Published by
Business Wire
12 Nov 12 RELY-ABLE® study demonstrates benefits of Pradaxa® (dabigatran etexilate) are maintained for over 4 years Boehringer Ingelheim
10 Nov 12 Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment+ shows up to 85% viral cure in Phase IIb study including patients with advanced liver disease Boehringer Ingelheim,
Published by
Business Wire
08 Nov 12 RELY-ABLE®: Unprecedented long-term data support safety profile and sustained efficacy of Pradaxa® for stroke prevention in AF Boehringer Ingelheim GmbH,
Published by
Business Wire
06 Nov 12 Safety and Efficacy of Pradaxa® (dabigatran etexilate) Reconfirmed in Clinical Setting for VTE Prevention After Total Knee or Hip Replacement Boehringer Ingelheim,
Published by
Business Wire
05 Nov 12 FDA and EMA Reaffirm Important Health Benefits and Safety of Pradaxa® (dabigatran etexilate) for Patients with Atrial Fibrillation Boehringer Ingelheim GmbH,
Published by
Business Wire
15 Oct 12 NICE recommends treatment with alteplase is started as early as possible, within 4.5 hours of onset of ischaemic stroke symptoms Boehringer Ingelheim
02 Oct 12 Analyses presented at EASD support Trajenta® (linagliptin) as effective and well-tolerated for patients with type 2 diabetes with different background therapies Boehringer Ingelheim,
Published by
Business Wire
01 Oct 12 Boehringer Ingelheim’s novel project transfer program enables fast track to launch for biopharmaceuticals Boehringer Ingelheim
12 Sep 12 Asian populations with atrial fibrillation (AF) benefit from better stroke prevention with Pradaxa® (dabigatran etexilate) compared to warfarin Boehringer Ingelheim GmbH,
Published by
Business Wire
03 Sep 12 New data show significant improvements in lung function using combination of tiotropium and olodaterolA in COPD patients Boehringer Ingelheim,
Published by
Business Wire
03 Sep 12 SPIRIVA®* celebrates 10 years of ongoing commitment to patients and advancing clinical innovation in COPD Boehringer Ingelheim,
Published by
Business Wire
03 Sep 12 Phase III results: tiotropiumA Respimat® significantly reduces exacerbations in asthma patients still symptomatic despite ICS/LABA treatment Boehringer Ingelheim,
Published by
Business Wire
29 Aug 12 Large scale registry shows atrial fibrillation management is suboptimal and unequal around the world Boehringer Ingelheim,
Published by
Business Wire
25 Jul 12 Jentadueto® (linagliptin/metformin hydrochloride) tablets receive approval for the treatment of adults with Type 2 Diabetes in Europe Boehringer Ingelheim,
Published by
Business Wire
28 Jun 12 New publication in The Lancet: Two-year study in over 1,500 patients compares Trajenta® (linagliptin) to the commonly prescribed sulphonylurea glimepiride Boehringer Ingelheim,
Published by
Business Wire
25 Jun 12 First randomised study to evaluate new oral anticoagulant for use in patients with mechanical heart valve Boehringer Ingelheim
09 Jun 12 New analysis presented at ADA shows improvement in albuminuria with linagliptin in patients at high risk of declining renal function Boehringer Ingelheim,
Published by
Business Wire
09 Jun 12 New linagliptin Phase III data demonstrate significant reductions in blood glucose with no additional risk of hypoglycaemia when combined with insulin in patients with type 2 diabetes Boehringer Ingelheim,
Published by
Business Wire
09 Jun 12 New data demonstrate sustained glucose reduction and weight loss up to 90 weeks with investigational SGLT-2 inhibitor, empagliflozin* Boehringer Ingelheim,
Published by
Business Wire
25 May 12 Jentadueto™ (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with Type 2 Diabetes in Europe Boehringer Ingelheim,
Published by
Business Wire
24 May 12 Promising phase II data with once-daily tiotropium may lead to new treatment option for adolescent asthma patients Boehringer Ingelheim,
Published by
Porter Novelli
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.